AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home iLIVER Article
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Editorial | Open Access

Multiomic predictors for regression of cirrhosis: Clinical implications and future directions

Binghua LiDecai Yu( )
Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
Show Author Information

References

[1]

Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005;42(Suppl(1)):S22–36. https://doi.org/10.1016/j.jhep.2004.12.008.

[2]

Lurje I, Gaisa NT, Weiskirchen R, et al. Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies. Mol Aspect Med 2023;92:101191. https://doi.org/10.1016/j.mam.2023.101191.

[3]

Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 2021;18(3):151–66. https://doi.org/10.1038/s41575-020-00372-7.

[4]

Caligiuri A, Gentilini A, Pastore M, et al. Cellular and molecular mechanisms underlying liver fibrosis regression. Cells 2021;10(10):2759. https://doi.org/10.3390/cells10102759.

[5]

Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 2022;75(5):1235–46. https://doi.org/10.1002/hep.32204.

[6]

Sun Y, Chen W, Chen S, et al. Regression of liver fibrosis in patients on hepatitis B therapy is associated with decreased liver-related events. Clin Gastroenterol Hepatol 2024;22(3):591–601.e3. https://doi.org/10.1016/j.cgh.2023.11.017.

[7]

Mendoza YP, Tsouka S, Semmler G, et al. Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression. JHepatol 2024;S0168-S8278(24):2334. https://doi.org/10.1016/j.jhep.2024.06.028.

[8]

Lee MJ. A review of liver fibrosis and cirrhosis regression. J Pathol Transl Med 2023;57(4):189–95. https://doi.org/10.4132/jptm.2023.05.24.

[9]

Li B, Li Y, Zhou H, et al. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology 2024;79(2):289–306. https://doi.org/10.1097/HEP.0000000000000553.

[10]

Dong XQ, Wu Z, Li J, et al. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: a 78-week prospective study. J Gastroenterol Hepatol 2019;34(4):755–63. https://doi.org/10.1111/jgh.14498.

iLIVER
Article number: 100116
Cite this article:
Li B, Yu D. Multiomic predictors for regression of cirrhosis: Clinical implications and future directions. iLIVER, 2024, 3(4): 100116. https://doi.org/10.1016/j.iliver.2024.100116

79

Views

0

Crossref

0

Scopus

Altmetrics

Received: 08 August 2024
Accepted: 09 August 2024
Published: 07 September 2024
© 2024 Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return